Levodopa‐induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls. Although the prevalence of severe LID appears to be lower than in previous eras (likely owing to a more conservative use of oral levodopa), we have not yet found a way to prevent the development of this complication. Advanced surgical therapies, such as deep brain stimulation, ameliorate LID, but only a minority of PD patients qualify for these interventions. Although some have argued that PD patients would rather be ON with dyskinesia than OFF, the deeper truth is that patients would very much prefer to be ON without dyskinesia. As researchers and clinicians, we should aspire to make that goal a reality. To this end, translational research on LID is to be encouraged and persistently pursued. © 2019 International Parkinson and Movement Disorder Society

中文翻译：

---

运动障碍很重要

左旋多巴引起的运动障碍 (LID) 是帕金森病 (PD) 患者感到不适的重要原因。它对生活质量产生负面影响，与运动和非运动波动有关，并会增加残疾、平衡问题和跌倒的风险。尽管重度 LID 的患病率似乎低于以前的时代（可能是由于口服左旋多巴的使用更为保守），但我们尚未找到预防这种并发症发展的方法。先进的手术疗法，例如深部脑刺激，可以改善 LID，但只有少数 PD 患者有资格接受这些干预。尽管有些人认为 PD 患者宁可在运动障碍时 ON，也不愿 OFF，但更深层次的事实是，患者更愿意在没有运动障碍的情况下 ON。作为研究人员和临床医生，我们应该渴望实现这一目标。为此，应鼓励并持续开展 LID 的转化研究。© 2019 国际帕金森和运动障碍协会